A Double-blind, Randomized, Placebo-controlled, Repeat Dose, 2-way Crossover Drug Interaction Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects Following Administration of Fluticasone Furoate/GW642444M Inhalation Powder With Ketoconazole.
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Ketoconazole
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 01 Nov 2012 Primary endpoint 'Cortisol-levels' has not been met.
- 01 Nov 2012 Primary endpoint 'Potassium-levels' has been met.
- 01 Nov 2012 Primary endpoint 'Heart-rate' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History